Jump to main content
Jump to site search

Issue 30, 2016
Previous Article Next Article

HP-β-cyclodextrin as an inhibitor of amyloid-β aggregation and toxicity

Author affiliations


Amyloid deposits of misfolded amyloid-β protein (Aβ) on neuronal cells are a pathological hallmark of Alzheimer's disease (AD). Prevention of the abnormal Aβ aggregation has been considered as a promising therapeutic strategy for AD treatment. To prevent reinventing the wheel, we proposed to search the existing drug database for other diseases to identify potential Aβ inhibitors. Herein, we reported the inhibitory activity of HP-β-cyclodextrin (HP-β-CD), a well-known sugar used in drug delivery, genetic vector, environmental protection and treatment of Niemann–Pick disease type C1 (NPC1), against Aβ1–42 aggregation and Aβ-induced toxicity, with the aim of adding a new function as a sugar-based Aβ inhibitor. Experimental data showed that HP-β-CD molecules were not only nontoxic to cells, but also greatly inhibited Aβ fibrillization and reduced Aβ-induced toxicity in a concentration-dependent manner. At an optimal molar ratio of Aβ : HP-β-CD = 1 : 2, HP-β-CD enabled the reduction of 60% of Aβ fibrils and increased the cell viability to 92%. Such concentration-dependent inhibitor capacity of HP-β-CD was likely attributed to several combined effects, including the enhancement of Aβ–HP-β-CD interactions, prevention of structural transition of Aβ peptides towards β-sheet structures, and reduction of self-aggregation of HP-β-CD. In parallel, molecular simulations further revealed the atomic details of HP-β-CD interacting with the Aβ oligomer, showing that HP-β-CD had a high tendency to interact with hydrophobic residues of Aβ in two β-strands and the N-terminal tail. More importantly, we identified that the inner hydrophobic cavity of HP-β-CD was a key active site for Aβ inhibition. Once the inner cavity of HP-β-CD was blocked by a small hydrophobic molecule of ferulic acid, HP-β-CD completely lost its inhibition capacity against Aβ. Given the already established pharmaceutical functions of HP-β-CD in drug delivery, our findings suggest that HP-β-CD has great potential to be designed as a sugar-based Aβ inhibitor.

Graphical abstract: HP-β-cyclodextrin as an inhibitor of amyloid-β aggregation and toxicity

Back to tab navigation

Article information

25 May 2016
27 Jun 2016
First published
28 Jun 2016

Phys. Chem. Chem. Phys., 2016,18, 20476-20485
Article type

HP-β-cyclodextrin as an inhibitor of amyloid-β aggregation and toxicity

B. Ren, B. Jiang, R. Hu, M. Zhang, H. Chen, J. Ma, Y. Sun, L. Jia and J. Zheng, Phys. Chem. Chem. Phys., 2016, 18, 20476
DOI: 10.1039/C6CP03582E

Social activity

Search articles by author